Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov;76(5):699-707.
doi: 10.1111/bcp.12110.

Histamine-induced vasodilatation in the human forearm vasculature

Euan A Sandilands  1 , Jane Crowe, Hayley Cuthbert, Paul J Jenkins, Neil R Johnston, Michael Eddleston, D Nicholas Bateman, David J Webb
Affiliations
Randomized Controlled Trial

Histamine-induced vasodilatation in the human forearm vasculature

Euan A Sandilands et al. Br J Clin Pharmacol. 2013 Nov.

Abstract

Aim: To investigate the mechanism of action of intra-arterial histamine in the human forearm vasculature.

Methods: Three studies were conducted to assess changes in forearm blood flow (FBF) using venous occlusion plethysmography in response to intra-brachial histamine. First, the dose-response was investigated by assessing FBF throughout a dose-escalating histamine infusion. Next, histamine was infused at a constant dose to assess acute tolerance. Finally, a four way, double-blind, randomized, placebo-controlled crossover study was conducted to assess FBF response to histamine in the presence of H1 - and H2 -receptor antagonists. Flare and itch were assessed in all studies.

Results: Histamine caused a dose-dependent increase in FBF, greatest with the highest dose (30 nmol min(-1) ) infused [mean (SEM) infused arm vs. control: 26.8 (5.3) vs. 2.6 ml min(-1) 100 ml(-1) ; P < 0.0001]. Dose-dependent flare and itch were demonstrated. Acute tolerance was not observed, with an increased FBF persisting throughout the infusion period. H2 -receptor antagonism significantly reduced FBF (mean (95% CI) difference from placebo at 30 nmol min(-1) histamine: -11.9 ml min(-1) 100 ml(-1) (-4.0, -19.8), P < 0.0001) and flare (mean (95% CI) difference from placebo: -403.7 cm(2) (-231.4, 576.0), P < 0.0001). No reduction in FBF or flare was observed in response to the H1 -receptor antagonist. Itch was unaffected by the treatments. Histamine did not stimulate vascular release of tissue plasminogen activator or von Willebrand factor.

Conclusion: Histamine causes dose-dependent vasodilatation, flare and itch in the human forearm. H2 -receptors are important in this process. Our results support further exploration of combined H1 - and H2 -receptor antagonist therapy in acute allergic syndromes.

Keywords: forearm blood flow; histamine; vasodilatation; venous occlusion plethysmography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) FBF in response to an i.a. histamine infusion. ▪ infused arm; □ control arm. (B) Flare and itch associated with an i.a. histamine infusion. □ flare; ○ itch
Figure 2
Figure 2
(A) Study of acute tolerance to i.a. histamine. ▪ infused arm; □ control arm. (B) Flare and itch associated with the continuous infusion of i.a. histamine. □ flare; ○ itch
Figure 3
Figure 3
FBF, flare and itch in the presence of histamine and histamine antagonists/placebo. formula image placebo; formula image H1-receptor antagonist; formula image H2-receptor antagonist; formula image H1- and H2-receptor antagonist
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr, Bock SA, Branum A, Brown SGA, Carmago CA, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD, Hepner DL, Lewis LM, Liebermen PL, Metcalfe DD, O'Conner R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FER, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117:391–397. - PubMed
    1. Bateman DN, Woodhouse KW, Rawlins MD. Adverse reactions to N-acetylcysteine. Hum Toxicol. 1984;3:393–398. - PubMed
    1. Waring WS, Stephen AF, Robinson OD, Dow MA, Pettie JM. Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high acetaminophen concentrations after overdose. Clin Toxicol (Phila) 2008;46:496–500. - PubMed
    1. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203–2217. - PubMed
    1. MacGlashan D., Jr Histamine: a mediator of inflammation. J Allergy Clin Immunol. 2003;112(4 Suppl):S53–59. - PubMed

Publication types

MeSH terms